I-Mab (IMAB)
| Market Cap | 996.71M |
| Revenue (ttm) | 13.75M |
| Net Income (ttm) | -364.30M |
| Shares Out | 82.65M |
| EPS (ttm) | -4.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,015,101 |
| Open | 12.23 |
| Previous Close | 12.70 |
| Day's Range | 11.98 - 12.68 |
| 52-Week Range | 10.14 - 85.40 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 87.37 (+624.5%) |
| Earnings Date | Mar 29, 2022 |
About IMAB
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and O...
Analyst Forecast
According to 22 analysts, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is 87.37, which is an increase of 624.46% from the latest price.
News
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md. , May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and comm...
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further a...
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md. , March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ...
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab Seven business dev...
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022
SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
Why I-Mab Shares Are Jumping Today
I-Mab (NASDAQ: IMAB) has provided updates on the recent development relating to the Holding Foreign Companies Accountable Act (HFCAA) and its implementation. I-Mab is not on this list, and it has taken...
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and c...
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Tre...
SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biolog...
SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients ...
SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...
I-Mab Announces Execution of Senior Management Team Share Purchase Plan
The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD ., Jan. 1...
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembroliz...
SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Announces Senior Management Team Share Purchase Plan
SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializati...
I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?
I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembroli...
SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Comme...
- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally renowned oncologist, appointed as P...
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa...
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Ho...
SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...
I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-H...
SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializatio...
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
SHANGHAI and GAITHERSBURG, Md. , Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patien...
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...
Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?
The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...